Skip to content

Author

A. Candreva

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Potent P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial.

BACKGROUND Dual antiplatelet therapy (DAPT) for 12 months is the current standard of care for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Recent evidence indicates that potent oral P2Y12 inhibitor-based single antiplatelet therapy (SAPT)...

J. F. Iglesias, B. Stähli, D. Heg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.